Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma - Takeaways - MDSpire

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma

  • By

  • Zhan Wang

  • Ze Zhao

  • Yang Yang

  • Yi Zhao

  • June 17, 2026

  • 0 min

Share

  • 1

    A folic acid-modified liposomal system was developed to coencapsulate doxorubicin and curcumin for targeted glioma therapy.

  • 2

    The Dox/Cur-Lip@FA system demonstrated high encapsulation efficiency and sustained drug release, enhancing therapeutic potential.

  • 3

    Curcumin effectively downregulated P-glycoprotein expression, reversing doxorubicin resistance in glioma cells.

  • 4

    In vivo studies showed a significant reduction in tumor volume with Dox/Cur-Lip@FA compared to free drugs and non-targeted liposomes.

  • 5

    This study highlights the potential of combining active targeting and multidrug resistance reversal for improved glioma treatment.

Original Source(s)

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma

  • by Zhan Wang, Ze Zhao, Yang Yang, Yi Zhao

  • June 17, 2026

Related Content

Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics

Malignant transformation of uterine serosal endometriosis to clear cell carcinoma in a postmenopausal patient: a rare case report

Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review